Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2007

View Archived Issues

Vinorelbine-cisplatin confirmed superior in stage II-IIIA NSCLC / News in Context

Eisai: Q3 report

Recent patents report new therapeutic agents for metabolic disorders

Recent Nissan Chemical patents describe new treatment options for thrombocytopenia

Axcan updates Q1 developments

ZymoGenetics' rhThrombin BLA accepted for review

SGX reviews oncology pipeline

Ark Therapeutics discusses phase III Vitor study with regulatory agencies

Valeant acquires rights to nabilone in the U.K. and Europe

KeyNeurotek and Max-Planck sign licensing agreement

Merck begins registrations of Atripla in developing countries

Inspire to commercialize AzaSite in U.S. and Canada

Gestiva reduces cervical shortening

Canarypox HIV vaccine responses in phase II not sufficient for phase III investigation

Pipex Pharmaceuticals' Coprexa awarded NIH grant for Alzheimer's disease

Post hoc subgroup analysis for Chrysalin in fracture repair

Safety, absorption of TMC-120 assessed in women with and without HIV

Traditional Chinese preparation to enter the clinic for the treatment of allergic asthma

New agents for treating neurological disorders disclosed in recent patents

Recent patents disclose novel treatments for diabetes

Cadherin-11: a potential target against rheumatoid arthritis

Cognitive and mood improvement after guarana therapy reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...